GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
Acta Diabetol
; 61(8): 941-950, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38831203
ABSTRACT
Type 2 diabetes represents a growing challenge for global public health. Its prevalence is increasing worldwide, and, like obesity, it affects progressively younger populations compared to the past, with potentially greater impact on chronic complications. Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge. Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity. In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores dos Hormônios Gastrointestinais
/
Polipeptídeo Inibidor Gástrico
/
Diabetes Mellitus Tipo 2
/
Receptor do Peptídeo Semelhante ao Glucagon 1
Limite:
Humans
Idioma:
En
Revista:
Acta Diabetol
Assunto da revista:
ENDOCRINOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália